Medikit Co.,Ltd. (TYO:7749)
Japan · Delayed Price · Currency is JPY 2,873.00
-16.00 (-0.55%)
Nov 26, 2025, 12:30 PM JST
Medikit Income Statement
Financials in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2016 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2016 - 2020 |
| 23,189 | 22,553 | 21,850 | 21,607 | 20,130 | 19,312 | Upgrade | |
Revenue Growth (YoY) | 4.03% | 3.22% | 1.13% | 7.34% | 4.24% | -2.92% | Upgrade |
Cost of Revenue | 14,237 | 13,885 | 13,098 | 13,289 | 11,949 | 11,720 | Upgrade |
Gross Profit | 8,952 | 8,668 | 8,752 | 8,318 | 8,181 | 7,592 | Upgrade |
Selling, General & Admin | 4,108 | 3,846 | 3,747 | 3,932 | 3,527 | 3,590 | Upgrade |
Amortization of Goodwill & Intangibles | 217 | 217 | 230 | 41 | - | - | Upgrade |
Operating Expenses | 4,444 | 4,182 | 4,077 | 4,204 | 3,762 | 3,817 | Upgrade |
Operating Income | 4,508 | 4,486 | 4,675 | 4,114 | 4,419 | 3,775 | Upgrade |
Interest Expense | -7 | -7 | -7 | -7 | -7 | -7 | Upgrade |
Interest & Investment Income | 50 | 32 | 19 | 18 | 40 | 19 | Upgrade |
Currency Exchange Gain (Loss) | 26 | 23 | -10 | -28 | -3 | - | Upgrade |
Other Non Operating Income (Expenses) | 110 | 99 | 84 | 63 | 84 | 69 | Upgrade |
EBT Excluding Unusual Items | 4,687 | 4,633 | 4,761 | 4,160 | 4,533 | 3,856 | Upgrade |
Gain (Loss) on Sale of Investments | - | - | -4 | 124 | -50 | 58 | Upgrade |
Gain (Loss) on Sale of Assets | 51 | 26 | 19 | 21 | -5 | 15 | Upgrade |
Asset Writedown | - | - | -1 | -15 | -5 | -1 | Upgrade |
Other Unusual Items | - | - | -1 | - | -1 | - | Upgrade |
Pretax Income | 4,738 | 4,659 | 4,774 | 4,290 | 4,472 | 3,928 | Upgrade |
Income Tax Expense | 1,653 | 1,646 | 1,705 | 1,426 | 1,479 | 1,269 | Upgrade |
Net Income | 3,085 | 3,013 | 3,069 | 2,864 | 2,993 | 2,659 | Upgrade |
Net Income to Common | 3,085 | 3,013 | 3,069 | 2,864 | 2,993 | 2,659 | Upgrade |
Net Income Growth | 1.92% | -1.82% | 7.16% | -4.31% | 12.56% | -7.90% | Upgrade |
Shares Outstanding (Basic) | 15 | 15 | 16 | 17 | 17 | 17 | Upgrade |
Shares Outstanding (Diluted) | 15 | 15 | 16 | 17 | 17 | 17 | Upgrade |
Shares Change (YoY) | -4.53% | -9.79% | -2.70% | -0.10% | -0.57% | -0.34% | Upgrade |
EPS (Basic) | 210.70 | 204.52 | 187.92 | 170.64 | 178.14 | 157.37 | Upgrade |
EPS (Diluted) | 210.70 | 204.52 | 187.92 | 170.64 | 178.14 | 157.37 | Upgrade |
EPS Growth | 6.75% | 8.83% | 10.13% | -4.21% | 13.20% | -7.58% | Upgrade |
Free Cash Flow | 376 | -256 | 3,146 | 3,497 | 1,374 | 2,093 | Upgrade |
Free Cash Flow Per Share | 25.68 | -17.38 | 192.64 | 208.35 | 81.78 | 123.87 | Upgrade |
Dividend Per Share | 45.000 | 90.000 | 80.000 | 70.000 | 60.000 | 50.000 | Upgrade |
Dividend Growth | -50.00% | 12.50% | 14.29% | 16.67% | 20.00% | - | Upgrade |
Gross Margin | 38.61% | 38.43% | 40.05% | 38.50% | 40.64% | 39.31% | Upgrade |
Operating Margin | 19.44% | 19.89% | 21.40% | 19.04% | 21.95% | 19.55% | Upgrade |
Profit Margin | 13.30% | 13.36% | 14.05% | 13.26% | 14.87% | 13.77% | Upgrade |
Free Cash Flow Margin | 1.62% | -1.14% | 14.40% | 16.18% | 6.83% | 10.84% | Upgrade |
EBITDA | 6,387 | 6,175 | 6,219 | 5,437 | 5,688 | 5,083 | Upgrade |
EBITDA Margin | 27.54% | 27.38% | 28.46% | 25.16% | 28.26% | 26.32% | Upgrade |
D&A For EBITDA | 1,879 | 1,689 | 1,544 | 1,323 | 1,269 | 1,308 | Upgrade |
EBIT | 4,508 | 4,486 | 4,675 | 4,114 | 4,419 | 3,775 | Upgrade |
EBIT Margin | 19.44% | 19.89% | 21.40% | 19.04% | 21.95% | 19.55% | Upgrade |
Effective Tax Rate | 34.89% | 35.33% | 35.71% | 33.24% | 33.07% | 32.31% | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.